Log in

NASDAQ:CASC - Cascadian Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+10.02 (+∞)
(As of 03/19/2018)
Today's Range
Now: $10.02
50-Day Range N/A
52-Week Range
Now: $10.02
Average Volume1.09 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:CASC



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive CASC News and Ratings via Email

Sign-up to receive the latest news and ratings for CASC and its competitors with MarketBeat's FREE daily newsletter.

Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions

What is Cascadian Therapeutics' stock symbol?

Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."

How were Cascadian Therapeutics' earnings last quarter?

Cascadian Therapeutics Inc (NASDAQ:CASC) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. During the same quarter last year, the business earned ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History.

Has Cascadian Therapeutics been receiving favorable news coverage?

News coverage about CASC stock has trended extremely negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cascadian Therapeutics earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cascadian Therapeutics.

Who are some of Cascadian Therapeutics' key competitors?

What other stocks do shareholders of Cascadian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cascadian Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), NIC (EGOV), ALJ Regional (ALJJ), Transocean (RIG) and Gran Tierra Energy (GTE).

Who are Cascadian Therapeutics' key executives?

Cascadian Therapeutics' management team includes the folowing people:
  • Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
  • Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
  • Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
  • Gary W. Christianson, Chief Operating Officer (Age 61)
  • Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
  • Robert W. Azelby, Director (Age 49)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
  • Steven P. James, Independent Director (Age 58)
  • Ted W. Love M.D., Independent Director (Age 58)
  • Daniel Keith Spiegelman, Independent Director (Age 58)

What is Cascadian Therapeutics' stock price today?

One share of CASC stock can currently be purchased for approximately $10.02.

What is Cascadian Therapeutics' official website?

The official website for Cascadian Therapeutics is http://www.cascadianrx.com/.

How can I contact Cascadian Therapeutics?

Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected]

MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  606
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel